- Home
- BANR vs LGND Comparison
BANR vs LGND Comparison
Compare BANR & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANR
- LGND
- Stock Information
- Founded
- BANR 1890
- LGND 1987
- Country
- BANR United States
- LGND United States
- Employees
- BANR N/A
- LGND N/A
- Industry
- BANR Major Banks
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- BANR Finance
- LGND Health Care
- Exchange
- BANR Nasdaq
- LGND Nasdaq
- Market Cap
- BANR N/A
- LGND 2.1B
- IPO Year
- BANR 1995
- LGND 1992
- Fundamental
- Price
- BANR $63.16
- LGND $102.51
- Analyst Decision
- BANR Buy
- LGND Strong Buy
- Analyst Count
- BANR 6
- LGND 7
- Target Price
- BANR $70.40
- LGND $144.67
- AVG Volume (30 Days)
- BANR 226.3K
- LGND 100.4K
- Earning Date
- BANR 04-16-2025
- LGND 05-08-2025
- Dividend Yield
- BANR 3.07%
- LGND N/A
- EPS Growth
- BANR 5.82
- LGND N/A
- EPS
- BANR 5.09
- LGND N/A
- Revenue
- BANR $614,045,000.00
- LGND $181,488,000.00
- Revenue This Year
- BANR $5.46
- LGND $16.47
- Revenue Next Year
- BANR $5.45
- LGND $19.44
- P/E Ratio
- BANR $12.17
- LGND N/A
- Revenue Growth
- BANR 3.98
- LGND 53.40
- 52 Week Low
- BANR $44.59
- LGND $72.61
- 52 Week High
- BANR $78.05
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- BANR 56.26
- LGND 42.08
- Support Level
- BANR $60.89
- LGND $102.50
- Resistance Level
- BANR $63.61
- LGND $111.42
- Average True Range (ATR)
- BANR 1.73
- LGND 3.87
- MACD
- BANR 0.36
- LGND -0.31
- Stochastic Oscillator
- BANR 86.46
- LGND 24.59
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.